Education
About Us
Working with TipRanks
Follow Us
Imv (Us) (IMVIF)
:IMVIF
IMVIF Stock Chart & Stats
$0.02
$0.00(0.00%)
At close: 4:00 PM EST
$0.02
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.01 - $0.02
Previous CloseN/A
Volume593.00
Average Volume (3M)3.35K
Market Cap
$9.51M
Enterprise ValueN/A
Total Cash (Recent Filing)$21.21M
Total Debt (Recent Filing)$28.90M
Price to Earnings (P/E)―
Beta3087.85
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,711,637
10 Day Avg. Volume0
30 Day Avg. Volume3,351
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IMVIF FAQ
What was Imv (Us)’s price range in the past 12 months?
Imv (Us) lowest stock price was $0.01 and its highest was $0.02 in the past 12 months.
What is Imv (Us)’s market cap?
Imv (Us)’s market cap is $9.51M.
When is Imv (Us)’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Imv (Us)’s earnings last quarter?
Currently, no data Available
Is Imv (Us) overvalued?
According to Wall Street analysts Imv (Us)’s price is currently Overvalued.
Does Imv (Us) pay dividends?
Imv (Us) does not currently pay dividends.
What is Imv (Us)’s EPS estimate?
Imv (Us)’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Imv (Us) have?
Imv (Us) has 11,711,637 shares outstanding.
What happened to Imv (Us)’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Imv (Us)?
Currently, no hedge funds are holding shares in IMVIF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Imv (Us)
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---